MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR trial
Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sough...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
5 February 2015
|
| In: |
Clinical cancer research
Year: 2015, Volume: 21, Issue: 9, Pages: 2057-2064 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-14-2737 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-14-2737 Verlag, kostenfrei, Volltext: http://clincancerres.aacrjournals.org/content/21/9/2057 
|
| Author Notes: | Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, Wolfgang Wick |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1560327316 | ||
| 003 | DE-627 | ||
| 005 | 20220813185247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170629s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-14-2737 |2 doi | |
| 035 | |a (DE-627)1560327316 | ||
| 035 | |a (DE-576)490327311 | ||
| 035 | |a (DE-599)BSZ490327311 | ||
| 035 | |a (OCoLC)1340976375 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Weller, Michael |d 1962- |e VerfasserIn |0 (DE-588)130838039 |0 (DE-627)506356701 |0 (DE-576)29836834X |4 aut | |
| 245 | 1 | 0 | |a MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma |b The DIRECTOR trial |c Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, Wolfgang Wick |
| 264 | 1 | |c 5 February 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.06.2017 | ||
| 520 | |a Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules. The DIRECTOR trial sought to show superiority of the 7/14 regimen. Experimental Design: Patients with glioblastoma at first progression after TMZ/RT→TMZ and at least two maintenance temozolomide cycles were randomized to Arm A [one week on (120 mg/m2 per day)/one week off] or Arm B [3 weeks on (80 mg/m2 per day)/one week off]. The primary endpoint was median time-to-treatment failure (TTF) defined as progression, premature temozolomide discontinuation for toxicity, or death from any cause. O6-methylguanine DNA methyltransferase (MGMT) promoter methylation was prospectively assessed by methylation-specific PCR. Results: Because of withdrawal of support, the trial was prematurely closed to accrual after 105 patients. There was a similar outcome in both arms for median TTF [A: 1.8 months; 95% confidence intervals (CI), 1.8-3.2 vs. B: 2.0 months; 95% CI, 1.8-3.5] and overall survival [A: 9.8 months (95% CI, 6.7-13.0) vs. B: 10.6 months (95% CI, 8.1-11.6)]. Median TTF in patients with MGMT-methylated tumors was 3.2 months (95% CI, 1.8-7.4) versus 1.8 months (95% CI, 1.8-2) in MGMT-unmethylated glioblastoma. Progression-free survival rates at 6 months (PFS-6) were 39.7% with versus 6.9% without MGMT promoter methylation. Conclusions: Temozolomide rechallenge is a treatment option for MGMT promoter-methylated recurrent glioblastoma. Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation. Clin Cancer Res; 21(9); 2057-64. ©2015 AACR. | ||
| 700 | 1 | |a Kästner, Bärbel |d 1969- |e VerfasserIn |0 (DE-588)120087855 |0 (DE-627)696368390 |0 (DE-576)29203475X |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a Platten, Michael |d 1971- |e VerfasserIn |0 (DE-588)121627780 |0 (DE-627)081431848 |0 (DE-576)261969811 |4 aut | |
| 700 | 1 | |a Hüsing, Johannes |d 1965- |e VerfasserIn |0 (DE-588)124519687 |0 (DE-627)36339270X |0 (DE-576)294211306 |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 21(2015), 9, Seite 2057-2064 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma The DIRECTOR trial |
| 773 | 1 | 8 | |g volume:21 |g year:2015 |g number:9 |g pages:2057-2064 |g extent:8 |a MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma The DIRECTOR trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-14-2737 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://clincancerres.aacrjournals.org/content/21/9/2057 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170629 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 28 |y j | ||
| 998 | |g 124519687 |a Hüsing, Johannes |m 124519687:Hüsing, Johannes |d 910000 |d 911400 |e 910000PH124519687 |e 911400PH124519687 |k 0/910000/ |k 1/910000/911400/ |p 26 | ||
| 998 | |g 121627780 |a Platten, Michael |m 121627780:Platten, Michael |d 910000 |d 911100 |e 910000PP121627780 |e 911100PP121627780 |k 0/910000/ |k 1/910000/911100/ |p 14 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |d 911100 |e 910000PW122759869 |e 911100PW122759869 |k 0/910000/ |k 1/910000/911100/ |p 6 | ||
| 998 | |g 120087855 |a Kästner, Bärbel |m 120087855:Kästner, Bärbel |d 910000 |d 911400 |e 910000PK120087855 |e 911400PK120087855 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 999 | |a KXP-PPN1560327316 |e 2972937198 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1560327316"],"doi":["10.1158/1078-0432.CCR-14-2737"]},"recId":"1560327316","origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"5 February 2015"}],"relHost":[{"origin":[{"dateIssuedKey":"1995","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedDisp":"1995-","publisher":"AACR"}],"id":{"zdb":["2036787-9"],"eki":["325489971"],"issn":["1557-3265"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"name":{"displayForm":["American Association for Cancer Research"]},"recId":"325489971","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1995 -"],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"disp":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma The DIRECTOR trialClinical cancer research","part":{"pages":"2057-2064","volume":"21","text":"21(2015), 9, Seite 2057-2064","year":"2015","extent":"8","issue":"9"}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Michael","display":"Weller, Michael","family":"Weller","role":"aut"},{"given":"Bärbel","display":"Kästner, Bärbel","family":"Kästner","role":"aut"},{"given":"Antje","role":"aut","family":"Wick","display":"Wick, Antje"},{"role":"aut","family":"Platten","display":"Platten, Michael","given":"Michael"},{"role":"aut","display":"Hüsing, Johannes","family":"Hüsing","given":"Johannes"},{"display":"Wick, Wolfgang","family":"Wick","role":"aut","given":"Wolfgang"}],"name":{"displayForm":["Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger, Wolfgang Wick"]},"note":["Gesehen am 29.06.2017"],"title":[{"subtitle":"The DIRECTOR trial","title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma","title_sort":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma"}],"language":["eng"],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a WELLERMICHMGMTPROMOT5201 | ||